Delcath Systems (OTC:DCTH) has closed on a $9.5 million private placement round, bringing the total amount raised since July to $29.5 million. The Queensbury, N.Y.-based company priced the round at $1,000 per unit, with each unit consisting of a preferred convertible share worth 16,667 common shares, at a 6¢ strike price, and a five-year warrant […]
BTG touts use of radiopaque drug-eluting bead
BTG (LON:BTG) said this month that an Australian patient was treated with its radiopaque drug-eluting bead. The DC Bead Lumi product is the first commercial drug-eluting bead that can be loaded with doxorubicin or irinotecan to treat tumors in patients with hepatocellular carcinoma and liver metastases from colorectal cancer, according to BTG. The beads’ radiopacity enable […]
Boston Scientific puts $4B on the table for BTG’s interventional portfolio
Boston Scientific (NYSE:BSX) said today that it agreed to offer $4.24 billion to acquire British medical device maker BTG (LON:BTG) and its portfolio of interventional drug-device therapies. The Marlborough, Mass.-based company said that its acquisition of BTG will augment Boston Scientific’s capabilities in the treatment of cancer and pulmonary embolism. “We are confident that the addition of these therapies […]
Medtech stories we missed this week: June 22, 2018
From Accuray’s India approval to Masimo and PositiveID launching a Bluetooth-enabled thermometer, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. India approves Accuray’s Radixact X9 radiation therapy device Accuray announced in a June 21 press release that it has received an Atomic Energy Regulatory Board Type Approval in […]
BTG touts one-year follow-up data for Ekos pulmonary embolism therapy
BTG (LON:BTG) touted results today from a one-year follow-up of pulmonary embolism patients who received the company’s Ekos therapy in its Optalyse PE trial. Researchers studied the 12-month outcomes of 101 patients who were treated over a shorter period and with smaller doses of thrombolytic drugs compared to the current standard. Pulmonary embolism patients treated with BTG’s Ekos […]
Researchers treat first cancer patients with BTG’s microscopic, drug-loaded beads
Researchers from the UCL Cancer Institute and BTG (LON:BTG) have started the first clinical trial of microscopic beads loaded with a targeted, cancer-fighting drug for patients with primary liver cancer or metastatic colorectal cancer. The trial is designed to evaluate the experimental therapy’s ability to deliver a precise amount of vandetanib directly to the arteries feeding […]
BTG helps fund immuno-oncology drug-device research programs
BTG (LON:BTG) and the Society of Interventional Oncology said today that it expanded its immuno-oncology/interventional oncology research grant program. The group launched a second round of funding, designed help evaluate minimally invasive, image-guided therapies that use the body’s own immune system to treat cancer. The program is specifically looking to fund proposals that assess how interventional […]
Study: Ekos ultrasound device provides relief to patients with chronic deep vein thrombosis
BTG (LON:BTG) touted data last week showing that patients with chronic deep vein thrombosis and post-thrombotic syndrome can be safely and effectively treated with the Ekos device and anti-coagulation drugs. The study’s protocol is the 1st treatment regimen proven to reduce the symptoms of PTS and demonstrate an improvement in quality of life for patients […]
BTG touts digital patient engagement platform with TheraSphere treatment
BTG (LON:BTG) touted data last week from a pilot study of its digital patient engagement platform IO Loop in patients with primary hepatocellular carcinoma undergoing treatment with the company’s TheraSphere transarterial radioembolization therapy. The study found that patients experienced sustained quality of life up to 3 months after treatment. The company touted the study of […]
Ultrasound-drug combo treats pulmonary embolism in less time with fewer drugs
When venous clots break off and travel through a patient’s circulatory system, they can become trapped in the lung and block blood flow. This strains the heart’s ability to pump blood through the lungs and can ultimately lead to heart failure. Traditionally, patients with pulmonary embolisms are treated overnight with systemic infusions of tissue plasminogen […]
Drug Delivery Business News
@DrugDeliveryNow
LinkedIn